【US Stock Movement】Pacira BioSciences surges on October 8: Viatris acquisition and cash tender offer

Pacira BioSciences Surges on October 8: Analysis

Keywords: Viatris acquisition, cash tender offer

1. On October 8, Viatris and Pacira BioSciences reached a definitive acquisition agreement under which Viatris will acquire all outstanding common shares of Pacira BioSciences for $36.50 per share in cash, valuing the equity of the deal at approximately $1.65 billion, representing a premium of about 45% over the previous trading day.

2. As of October 8, Pacira maintains two marketed, patent-protected, and high-margin U.S. drugs, EXPAREL and ZILRETTA. For the twelve months ended June 30, 2026, the company reported total revenue of approximately $746 million and adjusted EBITDA of around $177 million.

3. On October 8, Viatris stated it intends to leverage its intellectual property and global infrastructure to expand the market coverage of these products in select markets and expects the transaction will be immediately accretive to its financial guidance metrics.

(Disclaimer: This content is compiled and summarized by AI technology from public information and is for reference only. It does not constitute investment advice.)